AbbVie Analyst Ratings
BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $214
Jefferies Adjusts Price Target on Amgen to $380 From $375
HSBC Raises Price Target on Eli Lilly to $1,100 From $880, Maintains Buy Rating
Piper Sandler Maintains Overweight on Intuitive Surgical, Raises Price Target to $495
Piper Sandler Remains a Buy on Intuitive Surgical (ISRG)
JPMorgan Adjusts Price Target on Intuitive Surgical to $495 From $475, Maintains Overweight Rating
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)
Strong Performance and Growth Prospects Underpin Buy Rating for Intuitive Surgical
Barclays Maintains Overweight on Intuitive Surgical, Raises Price Target to $490
Intuitive Surgical Analyst Ratings
Barclays Remains a Buy on Intuitive Surgical (ISRG)
Morgan Stanley Maintains Equal-Weight on Intuitive Surgical, Raises Price Target to $460
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), GoodRx Holdings (GDRX) and Organon (OGN)
TD Cowen Adjusts Price Target on AbbVie to $195 From $180
TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793
Truist Raises Price Target on Intuitive Surgical to $515 From $450, Keeps Buy Rating
Truist Raises Price Target on Boston Scientific to $90 From $86, Maintains Buy Rating
Truist raised Humana's target price to $400.